Revenue falls, loss widens and operating cash flow turns negative
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited September 2026 results. Quarterly revenue fell to Rs 613.15 lakh from Rs 1,023.19 lakh, while net loss widened to Rs 257.33 lakh from Rs 83.65 lakh. Half-year revenue was Rs 1,572.79 lakh versus Rs 1,887.10 lakh, and net loss was Rs 302.88 lakh versus Rs 15.30 lakh profit. Operating cash outflow was Rs 593.29 lakh, against Rs 832.89 lakh inflow.
Weaker sales, a wider loss and cash outflow raise near-term pressure on the stock, partly offset by Rs 2,854.12 lakh of cash at September-end.